These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30885900)

  • 21. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States.
    Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.
    Fessel WJ; Anderson B; Follansbee SE; Winters MA; Lewis ST; Weinheimer SP; Petropoulos CJ; Shafer RW
    Antiviral Res; 2011 Dec; 92(3):484-7. PubMed ID: 22001594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals.
    DeJesus E; Towner WJ; Gathe JC; Cash RB; Anstett K
    J Acquir Immune Defic Syndr; 2024 Sep; ():. PubMed ID: 39250331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report.
    Dickter JK; Martin AL; Ho S; Ross JA; Shouse GP
    J Clin Pharm Ther; 2021 Aug; 46(4):1185-1187. PubMed ID: 34111306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):68-69. PubMed ID: 29667947
    [No Abstract]   [Full Text] [Related]  

  • 27. Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep.
    Morrow T
    Manag Care; 2018 Jun; 27(6):31-33. PubMed ID: 29989910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):360-382. PubMed ID: 38853601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection.
    Hiryak K; Koren DE
    Ann Pharmacother; 2021 Jun; 55(6):792-797. PubMed ID: 32964736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration.
    Zhu L; Huang B; Wang X; Ni F; Ao M; Wang R; Zheng B; Chen C; Xue J; Zhu L; Yang C; Shi L; Geng S; Hu J; Yang M; Zhang D; Yang P; Li M; Li Y; Hu Q; Ye S; Zheng P; Wei H; Wu Z; Zhang L; Wang Y; Liu Y; Wu X
    Nat Commun; 2024 Aug; 15(1):6961. PubMed ID: 39138183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.
    Iacob SA; Iacob DG
    Front Microbiol; 2017; 8():2323. PubMed ID: 29230203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):354-359. PubMed ID: 38853605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
    Bachelard A; Le Hingrat Q; Ferré VM; Lê M; Peytavin G; Damond F; Charpentier C; Fremont Goudot G; Goupil de Bouille J; Lariven S; Delobel P; Yazdanpanah Y; Descamps D; Matheron S; Ghosn J;
    Clin Infect Dis; 2024 Apr; 78(4):1005-1010. PubMed ID: 38630945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
    Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
    J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice.
    Imaz A; Falcó V; Ribera E
    AIDS Rev; 2011; 13(3):180-93. PubMed ID: 21799536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
    Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA
    Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.